Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-16-Speech-3-146-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20110216.11.3-146-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Mr President, I voted for the report by Mrs Matias, as it is vitally important to increase safety standards and establish effective, efficient and tough rules to prevent falsified medicinal products from entering the European Union. This is a requirement and a duty that we must fulfil on behalf of all European citizens, who are often unaware that they are buying a falsified medicine.
I agree with the thrust of the report, which introduces obligations to be met not only by distributors but also by all those involved in the supply chain. Indeed, it is often in the intricacies of the various steps in the distribution chain that high-risk products are introduced. Monitoring must not, however, only be carried out when products are placed on the market. Rather, inspections should take place at the sites where medicinal products and active ingredients are produced, including in third countries.
I do have one concern, however, which I must voice: I would have preferred the regulation to have regulated matters more effectively, by harmonising the various national laws, including online sales, in order to fully protect European consumers."@en1
|
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples